Background The debate over the overall benefits of self-monitoring of blood glucose in type 2 diabetes patients is still continuing.We aimed to assess the difference in glycaemic control and coronary heart disease （...Background The debate over the overall benefits of self-monitoring of blood glucose in type 2 diabetes patients is still continuing.We aimed to assess the difference in glycaemic control and coronary heart disease （CHD） risk levels of experimental type 2 diabetes patients provided with facilities for self-monitoring blood glucose and their counterparts without such facilities.Methods Sixty-one patients who had no prior experience in using glucometers were studied as intervention （n=30） and control （n=31） groups.The intervention group was trained in self-monitoring of blood glucose and documentation.Baseline blood glucose and fasting blood glucose were measured and the intervention patients were provided with glucometers and advised to self-monitor their fasting and postprandial blood glucose over six months.The 10-year CHD risk levels were determined with the United Kingdom Prospective Diabetes Study-derived risk engine calculator.Results The age and diabetes duration were similar in the two groups （P 〉0.05）.The majority of the patients were unemployed or retired females with only a primary level education.After 3 months,the haemogolbin A1c （HbA1c） levels of the control patients remained unchanged （（7.8±0.3）% vs.（7.9±0.4）%,P 〉0.05） whereas the HbA1c levels of the intervention patients were significantly reduced from the baseline at three （（9.6±0.3）% vs.（7.8±0.3）%,P 〈0.001） and six （（9.2±0.4）% vs.（7.5±0.3）%,P 〈0.001） months.Interestingly,while the 10-year CHD risk level of the control group remained unchanged after three months,that of the intervention group was remarkably reduced at three and six months from the baseline level （（7.4±1.3）% vs.（4.5±0.9）%,P=0.056）.Conclusion Self-monitoring of blood glucose in type 2 diabetes patients significantly improved glycaemic control and the CHD risk profile,suggesting that type 2 diabetes patients will potentially benefit from inclusion of glucose meters and testing strips in their health-care package.展开更多
文摘Background The debate over the overall benefits of self-monitoring of blood glucose in type 2 diabetes patients is still continuing.We aimed to assess the difference in glycaemic control and coronary heart disease （CHD） risk levels of experimental type 2 diabetes patients provided with facilities for self-monitoring blood glucose and their counterparts without such facilities.Methods Sixty-one patients who had no prior experience in using glucometers were studied as intervention （n=30） and control （n=31） groups.The intervention group was trained in self-monitoring of blood glucose and documentation.Baseline blood glucose and fasting blood glucose were measured and the intervention patients were provided with glucometers and advised to self-monitor their fasting and postprandial blood glucose over six months.The 10-year CHD risk levels were determined with the United Kingdom Prospective Diabetes Study-derived risk engine calculator.Results The age and diabetes duration were similar in the two groups （P 〉0.05）.The majority of the patients were unemployed or retired females with only a primary level education.After 3 months,the haemogolbin A1c （HbA1c） levels of the control patients remained unchanged （（7.8±0.3）% vs.（7.9±0.4）%,P 〉0.05） whereas the HbA1c levels of the intervention patients were significantly reduced from the baseline at three （（9.6±0.3）% vs.（7.8±0.3）%,P 〈0.001） and six （（9.2±0.4）% vs.（7.5±0.3）%,P 〈0.001） months.Interestingly,while the 10-year CHD risk level of the control group remained unchanged after three months,that of the intervention group was remarkably reduced at three and six months from the baseline level （（7.4±1.3）% vs.（4.5±0.9）%,P=0.056）.Conclusion Self-monitoring of blood glucose in type 2 diabetes patients significantly improved glycaemic control and the CHD risk profile,suggesting that type 2 diabetes patients will potentially benefit from inclusion of glucose meters and testing strips in their health-care package.
